BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sands BE, Han C, Gasink C, Jacobstein D, Szapary P, Gao LL, Lang Y, Targan S, Sandborn WJ, Feagan BG. The Effects of Ustekinumab on Health-related Quality of Life in Patients With Moderate to Severe Crohn's Disease. J Crohns Colitis 2018;12:883-95. [PMID: 29726939 DOI: 10.1093/ecco-jcc/jjy055] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Nocerino A, Nguyen A, Agrawal M, Mone A, Lakhani K, Swaminath A. Fatigue in Inflammatory Bowel Diseases: Etiologies and Management. Adv Ther 2020;37:97-112. [PMID: 31760611 DOI: 10.1007/s12325-019-01151-w] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 11.5] [Reference Citation Analysis]
2 Bian D, Jiang Y, Gu Y, He Z, Chen Q, Tang Y, Zhong J, Shi Y. Body Mass Index and Disease Activity Are Associated With Moderate to Severe Disability in Crohn's Disease: A Cross-Sectional Study in Shanghai. Front Med (Lausanne) 2021;8:662488. [PMID: 34307398 DOI: 10.3389/fmed.2021.662488] [Reference Citation Analysis]
3 Calviño-Suárez C, Ferreiro-Iglesias R, Bastón-Rey I, Barreiro-de Acosta M. Role of Quality of Life as Endpoint for Inflammatory Bowel Disease Treatment. Int J Environ Res Public Health 2021;18:7159. [PMID: 34281095 DOI: 10.3390/ijerph18137159] [Reference Citation Analysis]
4 Aladraj H, Abdulla M, Guraya SY, Guraya SS. Health-Related Quality of Life of Patients Treated with Biological Agents and New Small-Molecule Drugs for Moderate to Severe Crohn’s Disease: A Systematic Review. JCM 2022;11:3743. [DOI: 10.3390/jcm11133743] [Reference Citation Analysis]
5 Davies SC, Nguyen TM, Parker CE, MacDonald JK, Jairath V, Khanna R. Anti-IL-12/23p40 antibodies for maintenance of remission in Crohn's disease.Cochrane Database Syst Rev. 2019;12:CD012804. [PMID: 31828765 DOI: 10.1002/14651858.CD012804.pub2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Peyrin-Biroulet L, Louis E, Loftus EV Jr, Lacerda A, Zhou Q, Sanchez Gonzalez Y, Ghosh S. Quality of Life and Work Productivity Improvements with Upadacitinib: Phase 2b Evidence from Patients with Moderate to Severe Crohn's Disease. Adv Ther 2021;38:2339-52. [PMID: 33755884 DOI: 10.1007/s12325-021-01660-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Miyazaki C, Katsumasa N, Huang KC, Liu YF. Evaluation of economic burden with biologic treatments in Crohn's disease patients: A mirror image study using an insurance database in Japan. PLoS One 2021;16:e0254807. [PMID: 34280242 DOI: 10.1371/journal.pone.0254807] [Reference Citation Analysis]